TWI283582B - Expression potentiator for protein synthesis regulatory gene - Google Patents

Expression potentiator for protein synthesis regulatory gene Download PDF

Info

Publication number
TWI283582B
TWI283582B TW090125438A TW90125438A TWI283582B TW I283582 B TWI283582 B TW I283582B TW 090125438 A TW090125438 A TW 090125438A TW 90125438 A TW90125438 A TW 90125438A TW I283582 B TWI283582 B TW I283582B
Authority
TW
Taiwan
Prior art keywords
gene
subtype
ifn
expression
protein synthesis
Prior art date
Application number
TW090125438A
Other languages
English (en)
Chinese (zh)
Inventor
Yoshiaki Yanai
Osamu Sano
Masashi Kurimoto
Original Assignee
Hayashibara Biochem Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Biochem Lab filed Critical Hayashibara Biochem Lab
Application granted granted Critical
Publication of TWI283582B publication Critical patent/TWI283582B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
TW090125438A 2000-10-27 2001-10-15 Expression potentiator for protein synthesis regulatory gene TWI283582B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000328539 2000-10-27
JP2001116710A JP2002201141A (ja) 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤

Publications (1)

Publication Number Publication Date
TWI283582B true TWI283582B (en) 2007-07-11

Family

ID=26602905

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090125438A TWI283582B (en) 2000-10-27 2001-10-15 Expression potentiator for protein synthesis regulatory gene

Country Status (7)

Country Link
US (2) US6773701B2 (cg-RX-API-DMAC7.html)
EP (1) EP1329223A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002201141A (cg-RX-API-DMAC7.html)
KR (1) KR100830268B1 (cg-RX-API-DMAC7.html)
CA (1) CA2395324A1 (cg-RX-API-DMAC7.html)
TW (1) TWI283582B (cg-RX-API-DMAC7.html)
WO (1) WO2002036153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP4629964B2 (ja) * 2003-09-12 2011-02-09 株式会社林原生物化学研究所 ウシの消化器疾患治療剤
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
EP1867340A4 (en) 2005-03-10 2009-12-23 Hayashibara Biochem Lab THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM
JPWO2007037098A1 (ja) * 2005-09-27 2009-04-02 株式会社林原生物化学研究所 繁殖障害改善剤
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN104056254A (zh) * 2013-03-18 2014-09-24 赛德医药科技股份有限公司 用以降低肝炎病患复发率的组合物
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5142199B2 (cg-RX-API-DMAC7.html) 1972-09-04 1976-11-13
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
JPS5639022A (en) 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5654158A (en) 1979-10-09 1981-05-14 Hitachi Ltd Control system for call waiting
JP2838800B2 (ja) 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
JP3232488B2 (ja) 1992-08-20 2001-11-26 株式会社林原生物化学研究所 プルラン高含有物とその製造方法並びに用途
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH07163368A (ja) 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えdnaとその組換えdnaを含む形質転換体
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
JP3467515B2 (ja) * 1994-11-01 2003-11-17 財団法人ルイ・パストゥール医学研究センター インターフェロン活性の測定法
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
EP1329223A1 (en) 2003-07-23
KR100830268B1 (ko) 2008-05-16
US6773701B2 (en) 2004-08-10
US20040197307A1 (en) 2004-10-07
US7189389B2 (en) 2007-03-13
CA2395324A1 (en) 2002-05-10
KR20020065620A (ko) 2002-08-13
EP1329223A4 (en) 2005-04-20
JP2002201141A (ja) 2002-07-16
US20030039629A1 (en) 2003-02-27
WO2002036153A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
Lefevre et al. A novel and atypical type one interferon gene expressed by trophoblast during early pregnancy.
Sarkar et al. Novel functions of proteins encoded by viral stress-inducible genes
KR100947424B1 (ko) 신경계 질환의 치료 및/또는 예방을 위한 오스테오폰틴의용도
JP2019528284A (ja) 核酸産物およびその投与方法
JPS60143000A (ja) 改変ベ−タ−インタ−フエロン
CN103483443A (zh) 重组人干扰素样蛋白
EP4218787A2 (en) Peptides for treating muscle atrophy
KR100830268B1 (ko) 단백질 합성 억제 유전자의 발현 증강제
CN104292337A (zh) 猪融合干扰素
AU2005298245B2 (en) A thymus-specific protein
JPH0550273B2 (cg-RX-API-DMAC7.html)
CZ20024094A3 (cs) Farmaceutický přípravek pro léčení sclerosis multiplex obsahující nový interferon
Peek et al. Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro
US6231850B1 (en) Canine interleukin 12
CN101506232A (zh) 具有增强的生物活性的重组干扰素-β
Lu et al. Cloning and expression of canine interleukin-10
Zheng et al. Yak IFNβ-3 enhances macrophage activity and attenuates Klebsiella pneumoniae infection
ES2289303T3 (es) Factor de necrosis tumoral combinado con interferon en enfermedades desmielinantes.
RU2003334C1 (ru) Способ лечени больных с опухол ми
KR102096526B1 (ko) 식물 유래 dna 탈메틸효소를 이용한 동물세포에서의 인터페론의 발현 수준의 증가용 조성물, 항바이러스용 조성물, 및 이를 이용한 방법
KR101919314B1 (ko) 구제역 바이러스 백신 조성물
WO2026082097A1 (zh) 多肽、rna分子及其医药用途
CN116685598A (zh) 干扰素taufc-融合蛋白和治疗方法冠状病毒感染
JPWO2006093211A1 (ja) 抗ウイルス剤
Johnson et al. Genetic dissection of interferon signal transduction in human HeLa cell line

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees